Navigation Links
Insmed Incorporated Provides Regulatory Update
Date:10/10/2011

MONMOUTH JUNCTION, N.J., Oct. 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the clinical hold previously placed on Insmed's phase 3 clinical trials for ARIKACE® (liposomal amikacin for inhalation) in Cystic Fibrosis (CF) patients with Pseudomonas lung infections. Insmed has not yet received a response from FDA regarding the clinical hold previously placed on Insmed's phase 3 clinical trials for ARIKACE in patients with non-tuberculous mycobacterial (NTM) lung disease.  

As announced on August 1, 2011, the clinical holds placed on ARIKACE in CF and NTM were based on an initial review by FDA of the interim results of a long-term rat inhalation carcinogenicity study reported to the agency by Insmed with ARIKACE.  At that time, FDA requested additional information on ARIKACE and data from the rat study.  Insmed submitted its complete response to this request before the end of August.

Insmed has been informed by FDA that, based on its review of the information provided to date, including the rat inhalation carcinogenicity study results, the agency has insufficient information to assess the risks for ARIKACE in CF patients.  FDA has requested additional information from the Company, including that Insmed conduct a dog inhalational 9-month toxicity study of ARIKACE to determine if the findings of the rat inhalation carcinogenicity study are also demonstrated in a non-rodent model, and to propose a CF patient population/disease state where the risk-benefit profile of ARIKACE may be more favorable.

"Insmed is in the process of assessing the impact that FDA's recent requests and the continuation of the clinical hold will have on our phase 3 clinical trials for ARIKACE in CF," said Timothy Whitten, President and CEO of Insmed.  "Once we have a better un
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
7. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
8. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
9. Insmed to Host Third Quarter 2010 Conference Call
10. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
11. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 ... the "Pharmaceutical Contract Manufacturing - Global Strategic Business ... This report analyzes the worldwide markets for Pharmaceutical Contract ... Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms ... (Syrups, Suspensions, Gels, Creams & Ointments). The ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets ... by Type of Material, by Technology, by Application & by ... their offering. The demand for membranes is ... driving the market to $29.31 billion Membrane technology ... applications, such as water filtration and kidney dialysis. In modern ...
(Date:8/19/2014)... According to Kalorama Information, electronic medical records ... Data in healthcare a reality, and this a factor ... American Recovery and Reinvestment Act, the U.S. government dedicated ... penalties will start applying soon for use of paper ... study of the EMR industry, EMR 2014: The ...
Breaking Medicine Technology:Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2Global Membranes (MF, RO, UF, Gas Separation, Dialysis, NF) Market - Forecasts to 2019 2Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3
(Date:8/19/2014)... in multitasking and ways to train it have been ... universitaire de griatrie de Montral and the University of ... the effectiveness of this training. Cooking while having a ... driving while listening to a radio show ... Unfortunately, it decreases with age, which makes it harder ...
(Date:8/19/2014)... August 20, 2014 Recently, iFitDress.com,a leading ... outfits, has unveiled its new collection of pewter ... to expand the company’s global market. Each item is ... the company’s senior spokesman, customers that have specific requirements ... iFitDress.com. Now, all the brand new items are offered ...
(Date:8/19/2014)... -- Lupus and other rheumatic diseases can cause ... can delay a correct diagnosis for months, a ... can also cause these types of symptoms, according ... in Maywood, Ill. Rheumatic disorders include autoimmune and ... such as lupus, systemic vasculitis and ankylosing spondylitis. ...
(Date:8/19/2014)... from Glasgow where he helped distribute thousands of The ... 23 – August 6), Pete Dwan is a man with ... for his work cannot be overstated. , According to UK ... A drugs within the last year. And that doesn’t take ... to be “legal highs” until June 2014, when the UK ...
(Date:8/19/2014)... the longtime standard treatment for atrial fibrillation, is ... drug marketplace including dabigatran, rivaroxaban, and apixaban. A ... novel oral anticoagulants (NOACs) into clinical practice. By ... anticoagulant prescriptions yet this represents 98% of total ... The American Journal of Medicine . , Atrial ...
Breaking Medicine News(10 mins):Health News:Targeted brain training may help you multitask better 2Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:British Scientologist on a Mission to Save Youth from Drug Abuse 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3
... Oct. 15 Impelsys , a global ... American Academy of Pediatrics (AAP), a ... solidified its e-book strategy with iPublishCentral , ... 350 publishers worldwide. Launching in early 2010, AAP will ...
... DEERFIELD, Ill., October 14, 2009 A study, published ... showed that a greater percentage of patients with type ... (pioglitazone HCl and metformin HCl) as initial therapy reached ... percent compared to either component alone. Safety and tolerability ...
... at reducing the risk of heart attacks and heart ... new report from the Institute of Medicine. The ... secondhand smoke boosts nonsmokers, risk for heart problems, adding ... could lead to a heart attack is compelling. ...
... Program Seeks Adult Athletes to Go the Extra Mile to ... Teen and pre-teen girls face peer pressure, cultural stereotypes ... impact on their futures. That is why former Ironman ... prevention program that prepares girls for a lifetime of self-respect ...
... DIEGO, Oct. 15 Cardium Therapeutics (NYSE Amex: CXM ... to selected investors for aggregate gross proceeds of $6.0 million. ... was filed by Cardium Therapeutics with the Securities and Exchange ... August 15, 2007. Details concerning the terms of the ...
... tradition of capturing celebrity in photograph with 2009 Christmas ... Lung Association has brought back a time-honored tradition this ... a photograph with the 2009 Christmas Seal. This ... distinguished list of celebrities and entertainers who have served ...
Cached Medicine News:Health News:Leading Society Publisher, American Academy of Pediatrics, Chooses iPublishCentral to Launch e-Book Strategy 2Health News:Leading Society Publisher, American Academy of Pediatrics, Chooses iPublishCentral to Launch e-Book Strategy 3Health News:New data showed type 2 diabetes patients experienced greater blood sugar reductions 2Health News:New data showed type 2 diabetes patients experienced greater blood sugar reductions 3Health News:New data showed type 2 diabetes patients experienced greater blood sugar reductions 4Health News:New data showed type 2 diabetes patients experienced greater blood sugar reductions 5Health News:Smoking bans reduce the risk of heart attacks associated with secondhand smoke 2Health News:Girls on the Run Inspires Girls to Recognize and Achieve Their Potential Through the Power of Running 2Health News:Girls on the Run Inspires Girls to Recognize and Achieve Their Potential Through the Power of Running 3Health News:Cardium Announces $6.0 Million Registered Direct Offering 2Health News:Cardium Announces $6.0 Million Registered Direct Offering 3Health News:S. Epatha Merkerson Lends Star Power to Support the American Lung Association's Christmas Seals Campaign as Celebrity Chairperson 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: